Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 3/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KIT | P10721 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29394044 | 1.00 | GRM5 (0.42) | GRM5NAMPTPTGDR2KDM4ELMNA | |
| SCHEMBL30079789 | 1.00 | GRM5 (0.42) | GRM5NAMPTPTGDR2KDM4ELMNA | |
| SCHEMBL3411174 | 0.88 | NAMPT (0.46) | GRM5NAMPTPTGDR2 | |
| SCHEMBL7893824 | 0.84 | HSP90B1 (0.46) | GRM5NAMPT | |
| SCHEMBL3413024 | 0.83 | KIT (0.51) | GRM5NAMPTKIT | |
| SCHEMBL3417074 | 0.83 | GRM5 (0.44) | GRM5NAMPTPTGDR2TACR2TACR1 | |
| SCHEMBL3411310 | 0.82 | KIT (0.44) | GRM5NAMPTTACR2TACR1KIT | |
| SCHEMBL13117491 | 0.81 | NAMPT (0.42) | GRM5NAMPTKDM4ELMNAGLA | |
| SCHEMBL4315437 | 0.81 | MEN1 (0.53) | KDM4E | |
| SCHEMBL3416458 | 0.81 | GRM5 (0.50) | GRM5PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | claimed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | claimed |
| EP-3436009-B1 | NEGATIVE ALLOSTERIC MODULATORS OF MGLUR5 FOR USE IN THE TREATMENT OF MATURE BRAIN DAMAGES. | Sinntaxis AB (SE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023279193-A9 | PHOSPHODIESTERASE INHIBITORS FOR THE MITIGATION OF FRAGILE X SYNDROME SYMPTOMS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2023-04-27 | — | — | WO | disclosed |
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | Sinntaxis AB (SE) | 2021-06-15 | — | — | US | disclosed |
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | Sinntaxis AB (SE) | 2021-06-15 | — | — | US | disclosed |
| WO-2010124047-A1 | BISARYL ALKYNYLAMIDES AS NEGATIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | WYETH LLC (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11033545-B2 | Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages | GRM5, GRIK5, GRM1 | GRM5 1/4885NAMPT 704/4885PTGDR2 532/4885 |
| US-20100273772-A1 | Bisaryl Alkynylamides as Negative Allosteric Modulators of Metabotropic Glutamate Receptor 5 (MGLUR5) | GRM5, GRM1, GRM2 | GRM5 1/4885NAMPT 4640/4885PTGDR2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.